



Nucala[®] (mepolizumab) – Expanded indication

- On September 12, 2019, [GlaxoSmithKline](#) announced the [FDA approval](#) of [Nucala \(mepolizumab\)](#), add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.
 - Nucala was previously approved for this indication in patients 12 years of age and older.
 - Nucala is not indicated for the relief of acute bronchospasm or status asthmaticus.
- Nucala is also approved for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.
- The use of Nucala in children aged 6 to 11 years with severe asthma, and with an eosinophilic phenotype, is supported by evidence from adequate and well-controlled trials in adults and adolescents with additional pharmacokinetic, pharmacodynamic, and safety data in children aged 6 to 11 years. Based upon the pharmacokinetic data from this trial, a dose of 40 mg subcutaneous (SC) every 4 weeks was determined to have similar exposure to adults and adolescents administered a dose of 100 mg SC.
 - The efficacy of Nucala in children aged 6 to 11 years is extrapolated from efficacy in adults and adolescents with support from pharmacokinetic analyses showing similar drug exposure levels for 40 mg administered SC every 4 weeks in children aged 6 to 11 years compared with adults and adolescents.
- The recommended dose of Nucala for the treatment of severe asthma in patients aged 6 to 11 years is 40 mg administered once every 4 weeks by SC injection into the upper arm, thigh, or abdomen.
 - Refer to the Nucala drug label for dosing for all other indications.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.